Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CV Sciences Q3 2026 Results: Net Loss of $93K, Loss Narrows

CV Sciences reported a net loss of $1.5 million for the nine months ended September 30, 2026, compared to a loss of $0.8 million in the prior year period, primarily driven by a decrease in product sales and non-cash losses on debt conversions. Despite the net loss, the company generated positive cash flow from operations of $0.18 million and recorded a $0.5 million gain from a legal settlement during the third quarter.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.03.3
Gross profit1.51.6
Profit before tax-0.1-0.4
Net income-0.1-0.4
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-7.0%
Gross margin50.0%
Operating margin12.5%
Source

10-Q filed with the SEC, OTC: CVSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CV Sciences, Inc.: key numbers

Share price
$0.0096Close, Nov 16
Market cap
$2.32M
Shares outstanding
242.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CV Sciences, Inc.

All →
4:28 PM ET Form 4
Insider Buying

CV Sciences Insider Charlie E. Cheever III Buys $45.6K of Stock

Charlie E. Cheever III bought 4,557,721 shares of CV Sciences, Inc. at $0.01 a share, worth $45.6K in total between Nov 4, 2026 and Nov 9, 2026. Shares held after the trade: 31,706,432 (+6.7%).

Value
$45.6K
Shares
4,557,721
Average price
$0.0100
Holding change
+6.7%
Trade date
Nov 4, 2026 to Nov 9, 2026
4:04 PM ET 8-K
Financial Results

CV Sciences Financial Results

CV Sciences reported third quarter 2026 revenue of $3.0 million, a 7% decrease year-over-year due to restrictive regulations and lower sales volumes. Despite the revenue decline, the company achieved positive adjusted EBITDA of $32,000 and expanded gross margins to 50.0% through cost discipline and operational efficiency.

Term
Q3 2026

“Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue. We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026.”

Joseph Dowling, Chief Executive Officer

“Looking ahead, we remain focused on strengthening our established brands, expanding our presence in broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities that support sustainable growth and long-term shareholder value.”

Joseph Dowling, Chief Executive Officer
4:42 PM ET 8-K
Court & Legal Update

CV Sciences Court & Legal Update

CV Sciences has settled an arbitration case initiated in February 2025 against its former legal counsel. Under the settlement terms, the company received $500,000 and both parties have mutually released all claims against each other.

Counterparty
former legal counsel

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.